CUF, a herbal formula for the treatment of asthma: A randomized, double-blind, placebo-controlled study in the treatment of childhood asthma ()
1. INTRODUCTION
Fowl Pox Virus belongs to the Avipoxviridae viral family [1]. The disease it causes is a major cause of economic losses in poultry, because it results in drop in egg production, weight loss and poor carcass quality due to the lesions it causes on dressed chicken.
Pox disease in chicks manifests in two forms. Cutaneous pox occurs on the unfeathered parts of affected birds’ bodies (heads, combs and wattles), while the diphtheritic form leads to lesions (canker) in mucous membranes of the mouth, larynx and trachea [2]. The diphtheritic lesions in the trachea are often confused with lesions of avian herpesvirus or lesions of Infectious laryngotracheitis [3].
Avipoxviruses are among the largest and most complex animal viruses and have worldwide distribution. Pox disease has been reported to affect over 232 species in 23 orders of birds, including chickens, turkeys and pigeons [4].
In chickens, fowl pox affects all ages, all sexes and all breeds. There is at present no treatment for the disease. Antibiotics are used just to control secondary bacterial infections and vitamin A helps to heal the lesions [5].
Aluminum-Magnesium Silicate (AMS) is safe for use on food animals [6]. Vanderbilt [7] also reported that AMS is used to bind drugs into tablets which are used in treating humans and animals. So, the chemical is safe for use in animals and humans, as medicine.
Molecules of AMS have negative electrical charges on their surfaces and the positive charges on their edges [8]. Since viruses also have electrical charges [9], if AMS is used as medicine, extracellular viruses may adsorb onto it and thus fail to attach to host cells. This would inhibit infection at the stage of attachment of the virus to host cells.
The Synthetic AMS got from reaction of Aluminum silicate and Magnesium silicate [10] has exhibited antiviral effects against all four viral families, so far tested, including, Paramyxoviridae, Birnaviridae, Parvoviridae and Othomyxoviridae [10]. A need therefore exists to test it against other viral families.
2. MATERIALS AND METHODS
Five batches of fowl pox vaccine (National Veterinary Research Institute, Vom, Nigeria) were each reconstituted with PBS, at the rate of 5 ml for each 200 doses. Four ml of each of the reconstituted vaccines was mixed with equal volume (4 g) of The Synthetic AMS [10] and kept at room temperature for one hour. The mixtures were then centrifuged for 10 minutes, at 2000 revolutions per minute. The incubation of Fowl Pox Virus with AMS was repeated by mixing a volume of supernatants of the vaccines (2 ml) with equal amount of the AMS (2 g). The mixtures were again incubated at room temperature and centrifuged.
Modified passive haemagglutination test (MPHA) already described [11] was used to test the vaccine supernatants, for virus titres. Portions of the vaccines which were not incubated with the AMS served as controls. Mean titre of FPV in the portions of the vaccines not incubated with the AMS (controls) and means of the virus in the vaccines after the first and the second incubations, were tested for statistical differences, by Analysis of variance.
3. RESULTS
Incubating fowl pox vaccines with Aluminum-Magnesium Silicate significantly (P < 0.05) increased viral titres of the vaccines from a mean of 2.8 ± 1.10 to 11. 2 ± 4.38 but when incubation with the AMS was repeated, viral titres of all the vaccine batches reduced (P < 0.05) to zero (Table 1).
4. DISCUSSION
Fowl pox disease is one of the greatest challenges facing the poultry industry, especially in developing countries. This is mainly due to poor biosecurity measures available in those countries. Like most other viral diseases, it has no treatment. It is therefore important to search for antiviral agents that can inhibit the virus and cure infected chicks or prevent spread of infection in infected flocks.
In replication cycle of Fowl Pox Virus, after the viral
Table 1. Modified Passive Haemagglutination titres of Fowl Pox Virus in the vaccines, incubated with The Synthetic AluminumMagnesium Silicate.
Incubating cultured Fowl Pox Virus with The Synthetic AMS increased (P < 0.05) their titre initially but a repeat incubation with the chemical reduced (P < 0.05) the titre.
materials have assembled, the new virions get released by two methods. Some virions bud off the host cells completely while others remain attached on surfaces of the cells [5]. Viruses that remain attached to host cells would not be able to sensitize (infect) RBCs and so would not produce passive agglutination of the RBCs. So, their presence would not be detected by the passive haemagglutination test. AMS has been reported to assist in disintergrating capsules within gastrointestinal tract of treated patients [7]. It is therefore possible that the first incubation with the AMS leads to disintegration of the cells used to culture the Fowl Pox Virus in the process of vaccine production, and so, releases virions that are still attached to surfaces of the cells. Fowl Pox Viruses, released from the cells, may have sensitized the sheep RBCs at higher dilutions of the vaccine supernatants, thus leading to the significant increase of viral titres of the vaccines, from 2.8 ± 1.10 to 11.8 ± 4.38.
The observation that when samples of some viruses are incubated with The Synthetic AMS, their viral titres increase instead of reducing was also made [12] when it was used to incubate vaccines of Peste des Petits Ruminants Virus (PPRV). PPRV is one of the morbilliviruses which have close association with cells [13] as FPV does. Molecules of Aluminum-Magnesium Silicate are composed of platelets that are only 0.96 nm thick [7]. So, AMS is made of Nanoparticles [14] which have been reported to selectively deliver drugs to cancer cells [15]. The Synthetic AMS used in this study has been used for in vivo treatment of chicks, dogs, mice and rats [16-23] without adverse side effects on treated animals. That suggests that it is safe to healthy cells. So, its ability to disintegrate cells infected with PPRV and those infected with FPV to release associating virions suggests that it may also have the ability to act selectively on abnormal cells. So, it may be among the Nanoparticles which have anticancer potentials. Its affinity for infected cells would also aid its antiviral effects, as it would disintegrate infected cells and thereafter, adsorb virions released from the cells.
The zero titre got following a repeat incubation of the vaccines with the AMS suggests that AMS was able to inhibit FPV completely. This result agrees with earlier results got with use of the AMS on Peste des Petits Ruminants Virus [24], Infectious Bursa Disease virus [16], Canine parvovirus [17], Egg Drop Syndrome Virus [25], Newcastle disease Virus [18] and Avian Influenza virus [26]. Chenicoff and Venkatachrisnan [8] reported that Aluminum-Magnesium Silicate molecules poss both positive and negative electrically charged ends. Viral genomes also have electrical charges [9]. So particles of the FPV and the other viruses so far tested may have adsorbed molecules of the AMS, by electrostatic attraction, and so, were removed from supernatants of the viral samples. The results suggest that AMS is an antiviral agent against Fowl Pox Virus and can be used for treatment and control of fowl pox disease.